The Experts below are selected from a list of 4713 Experts worldwide ranked by ideXlab platform
Sun Och Yoon - One of the best experts on this subject based on the ideXlab platform.
-
proposal of an appropriate Decalcification method of bone marrow biopsy specimens in the era of expanding genetic molecular study
Journal of pathology and translational medicine, 2015Co-Authors: Sung Eun Choi, Soon Won Hong, Sun Och YoonAbstract:Sampling bone tissue is usually performed for the diagnosis of hematologic malignancy, metastatic tumor, or primary bone tumor. The processing of bone specimens usually follows Decalcification and microtome sectioning in pathology laboratories. Inorganic acids such as nitric acid or HCl are used in Decalcification, and limit diagnostic options by damaging DNA and RNA. As a result, gene testing is usually not plausible with these decalcified bone specimens, even though certain cancers need further genetic studies for diagnostic and therapeutic purposes. Therefore, there is a growing need for new Decalcification agents that adequately preserve DNA and RNA [1-3]. A variety of molecular testing techniques are necessary to diagnose hematologic malignancies. Fluorescence in situ hybridization, gene rearrangement studies of immunoglobulin and T cell receptor genes, and in situ hybridization for kappa and lambda light chains and Epstein-Barr virus–encoded small RNAs are commonly used molecular tools in diagnosis of hematologic malignancies. However, further molecular study from bone marrow biopsy specimens is often impossible due to DNA or RNA damage by Decalcification. Furthermore, immunohistochemistry may be required for differentiating and subtyping hematolymphoid lesions in conjunction with histomorphologic features of paratrabecular, interstitial, intrasinusoidal, or intravascular aggregates within bone marrow structures. HCl degrades both protein quality and quantity, resulting in poor immunohistochemical staining that cannot be used for accurate diagnosis. With consideration of these limitations, we evaluated modified bone marrow Decalcification protocols and compared them to the HCl method.
-
proposal of an appropriate Decalcification method of bone marrow biopsy specimens in the era of expanding genetic molecular study
Journal of pathology and translational medicine, 2015Co-Authors: Sung Eun Choi, Soon Won Hong, Sun Och YoonAbstract:Background The conventional method for Decalcification of bone specimens uses hydrochloric acid (HCl) and is notorious for damaging cellular RNA, DNA, and proteins, thus complicating molecular and immunohistochemical analyses. A method that can effectively decalcify while preserving genetic material is necessary. Methods Pairs of bilateral bone marrow biopsies sampled from 53 patients were decalcified according to protocols of two comparison groups: EDTA versus HCl and RDO GOLD (RDO) versus HCl. Pairs of right and left bone marrow biopsy samples harvested from 28 cases were allocated into the EDTA versus HCl comparison group, and 25 cases to the RDO versus HCl comparison group. The Decalcification protocols were compared with regards to histomorphology, immunohistochemistry, and molecular analysis. For molecular analysis, we randomly selected 5 cases from the EDTA versus HCl and RDO versus HCl groups. Results The Decalcification time for appropriate histomorphologic analysis was the longest in the EDTA method and the shortest in the RDO method. EDTA was superior to RDO or HCl in DNA yield and integrity, assessed via DNA extraction, polymerase chain reaction, and silver in situ hybridization using DNA probes. The EDTA method maintained intact nuclear protein staining on immunohistochemistry, while the HCl method produced poor quality images. Staining after the RDO method had equivocal results. RNA in situ hybridization using kappa and lambda RNA probes measured RNA integrity; the EDTA and RDO method had the best quality, followed by HCl. Conclusions The EDTA protocol would be the best in preserving genetic material. RDO may be an acceptable alternative when rapid Decalcification is necessary.
S U Qizhi - One of the best experts on this subject based on the ideXlab platform.
-
clinical application of casein phosphopeptide amorphic calcium phosphate in preventing enamel Decalcification in orthodontics
Chinese Journal of Orthodontics, 2011Co-Authors: J Wang, Yan Yan, Xiujing Wang, S U QizhiAbstract:Objective To evaluate the preventive effect of Casein Phosphopeptide-Amorphic Calcium Phosphate (CPP-ACP)in reducing enamel Decalcification in orthodontics.Methods Sixty orthodontic patients were divided into trial group and control group randomly.Patients in trial group were given oral hygiene education and GC tooth protector (mainly CPP-ACP).Patients in control group were given oral hygiene education only.Pictures were taken and the extents of enamel Decalcification between two the groups were compared one year after orthodontic treatment.Results The Decalcification index in trial group was 0.019 ± 0.033 and that in control group was 0.067 ± 0.039.The difference was significant (F=9.1,P＜0.01).Conclusions Casein PhosphopeptideAmorphic Calcium Phosphate could prevent enamel Decalcification in orthodontics. Key words: Casein phosphopetide-amorphic calcium phosphate; Enamel Decalcification; Orthodontics
Sung Eun Choi - One of the best experts on this subject based on the ideXlab platform.
-
proposal of an appropriate Decalcification method of bone marrow biopsy specimens in the era of expanding genetic molecular study
Journal of pathology and translational medicine, 2015Co-Authors: Sung Eun Choi, Soon Won Hong, Sun Och YoonAbstract:Sampling bone tissue is usually performed for the diagnosis of hematologic malignancy, metastatic tumor, or primary bone tumor. The processing of bone specimens usually follows Decalcification and microtome sectioning in pathology laboratories. Inorganic acids such as nitric acid or HCl are used in Decalcification, and limit diagnostic options by damaging DNA and RNA. As a result, gene testing is usually not plausible with these decalcified bone specimens, even though certain cancers need further genetic studies for diagnostic and therapeutic purposes. Therefore, there is a growing need for new Decalcification agents that adequately preserve DNA and RNA [1-3]. A variety of molecular testing techniques are necessary to diagnose hematologic malignancies. Fluorescence in situ hybridization, gene rearrangement studies of immunoglobulin and T cell receptor genes, and in situ hybridization for kappa and lambda light chains and Epstein-Barr virus–encoded small RNAs are commonly used molecular tools in diagnosis of hematologic malignancies. However, further molecular study from bone marrow biopsy specimens is often impossible due to DNA or RNA damage by Decalcification. Furthermore, immunohistochemistry may be required for differentiating and subtyping hematolymphoid lesions in conjunction with histomorphologic features of paratrabecular, interstitial, intrasinusoidal, or intravascular aggregates within bone marrow structures. HCl degrades both protein quality and quantity, resulting in poor immunohistochemical staining that cannot be used for accurate diagnosis. With consideration of these limitations, we evaluated modified bone marrow Decalcification protocols and compared them to the HCl method.
-
proposal of an appropriate Decalcification method of bone marrow biopsy specimens in the era of expanding genetic molecular study
Journal of pathology and translational medicine, 2015Co-Authors: Sung Eun Choi, Soon Won Hong, Sun Och YoonAbstract:Background The conventional method for Decalcification of bone specimens uses hydrochloric acid (HCl) and is notorious for damaging cellular RNA, DNA, and proteins, thus complicating molecular and immunohistochemical analyses. A method that can effectively decalcify while preserving genetic material is necessary. Methods Pairs of bilateral bone marrow biopsies sampled from 53 patients were decalcified according to protocols of two comparison groups: EDTA versus HCl and RDO GOLD (RDO) versus HCl. Pairs of right and left bone marrow biopsy samples harvested from 28 cases were allocated into the EDTA versus HCl comparison group, and 25 cases to the RDO versus HCl comparison group. The Decalcification protocols were compared with regards to histomorphology, immunohistochemistry, and molecular analysis. For molecular analysis, we randomly selected 5 cases from the EDTA versus HCl and RDO versus HCl groups. Results The Decalcification time for appropriate histomorphologic analysis was the longest in the EDTA method and the shortest in the RDO method. EDTA was superior to RDO or HCl in DNA yield and integrity, assessed via DNA extraction, polymerase chain reaction, and silver in situ hybridization using DNA probes. The EDTA method maintained intact nuclear protein staining on immunohistochemistry, while the HCl method produced poor quality images. Staining after the RDO method had equivocal results. RNA in situ hybridization using kappa and lambda RNA probes measured RNA integrity; the EDTA and RDO method had the best quality, followed by HCl. Conclusions The EDTA protocol would be the best in preserving genetic material. RDO may be an acceptable alternative when rapid Decalcification is necessary.
J Wang - One of the best experts on this subject based on the ideXlab platform.
-
clinical evaluation of remineralization potential of casein phosphopeptide amorphous calcium phosphate nanocomplexes for enamel Decalcification in orthodontics
Chinese Medical Journal, 2012Co-Authors: J Wang, Yan Yan, Xiujing WangAbstract:Background: Enamel Decalcification in orthodontics is a concern for dentists and methods to remineralize these lesions are the focus of intense research. The aim of this study was to evaluate the remineralizing effect of casein phosphopeptide amorphous calcium phosphate (CPP-ACP) nanocomplexes on enamel Decalcification in orthodontics. Methods: Twenty orthodontic patients with decalcified enamel lesions during fixed orthodontic therapy were recruited to this study as test group and twenty orthodontic patients with the similar condition as control group. GC Tooth Mousse, the main component of which is CPP-ACP, was used by each patient of test group every night after tooth-brushing for six months. For control group, each patient was asked to brush teeth with toothpaste containing 1100 parts per million (ppm) of fluoride twice a day. Standardized intraoral images were taken for all patients and the extent of enamel Decalcification was evaluated before and after treatment over this study period. Measurements were statistically compared by t test. Results: After using CPP-ACP for six months, the enamel Decalcification index (EDI) of all patients had decreased; the mean EDI before using CPP-ACP was 0.191 ± 0.025 and that after using CPP-ACP was 0.183 ± 0.023, the difference was significant (t = 5.169, P 0.05). Conclusion: CPP-ACP can effectively improve the demineralized enamel lesions during orthodontic treatment, so it has some remineralization potential for enamel Decalcification in orthodontics.
-
clinical application of casein phosphopeptide amorphic calcium phosphate in preventing enamel Decalcification in orthodontics
Chinese Journal of Orthodontics, 2011Co-Authors: J Wang, Yan Yan, Xiujing Wang, S U QizhiAbstract:Objective To evaluate the preventive effect of Casein Phosphopeptide-Amorphic Calcium Phosphate (CPP-ACP)in reducing enamel Decalcification in orthodontics.Methods Sixty orthodontic patients were divided into trial group and control group randomly.Patients in trial group were given oral hygiene education and GC tooth protector (mainly CPP-ACP).Patients in control group were given oral hygiene education only.Pictures were taken and the extents of enamel Decalcification between two the groups were compared one year after orthodontic treatment.Results The Decalcification index in trial group was 0.019 ± 0.033 and that in control group was 0.067 ± 0.039.The difference was significant (F=9.1,P＜0.01).Conclusions Casein PhosphopeptideAmorphic Calcium Phosphate could prevent enamel Decalcification in orthodontics. Key words: Casein phosphopetide-amorphic calcium phosphate; Enamel Decalcification; Orthodontics
Henk M W Verheul - One of the best experts on this subject based on the ideXlab platform.
-
Decalcification of breast cancer bone metastases with edta does not affect er pr and her2 results
The American Journal of Surgical Pathology, 2019Co-Authors: Suzanne C Van Es, Bert Van Der Vegt, Frederike Bensch, Sophie Gerritse, Erik J Van Helden, Eline Boon, Lindsay Angus, Jelle Overbosch, Catharina Menkevan Der Houven W Van Oordt, Henk M W VerheulAbstract:In metastatic breast cancer (MBC), expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor-2 (HER2) guides treatment selection. In case of bone-only metastatic disease, ER, PR, and HER2 status assessment may be hampered by Decalcification. We aimed to determine the optimal Decalcification method, and to study discordance of receptor expression between paired primary breast tumors and optimally decalcified bone metastases. First, Decalcification was simulated using acetic acid, hydrochloric/formic acid, and EDTA on 12 primary breast carcinomas. ER, PR, and HER2 immunohistochemistry (IHC) and HER2 in situ hybridization (ISH) were assessed, before and after the 3 Decalcification methods. EDTA was considered the optimal method, as it did not affect IHC and as ISH failed in only 1/16 cases. Hydrochloric/formic acid altered ER and PR results, and, with acetic acid and hydrochloric/formic acid, ISH failed in, respectively, 94% and 100%. Second, ER, PR, and HER2 IHC was performed in paired primary tumors and EDTA-decalcified bone metastases obtained from patients with first presentation of MBC. Clinically relevant discordance was defined as changed receptor status with treatment implications. Paired samples of 77 patients, participating in the IMPACT-MBC trial, were evaluable. Hormonal receptor expression change was clinically relevant in 6 patients (7.9%) and HER2 expression change in 1 patient (1.3%). This study shows that EDTA Decalcification minimally affects receptor expression results. The incidence of clinically relevant discordance between the primary tumor and bone metastases is low. These findings support that bone biopsies can reliably be used to assess receptor status.
-
Decalcification of breast cancer bone metastases with edta does not affect er pr and her2 results
VSNU Open Access deal, 2019Co-Authors: Suzanne C Van Es, Frederike Bensch, Sophie Gerritse, Erik J Van Helden, Eline Boon, Lindsay Angus, Jelle Overbosch, Catharina Menkevan Der Houven W Van Oordt, B Van Devegt, Henk M W VerheulAbstract:textabstractIn metastatic breast cancer (MBC), expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor-2 (HER2) guides treatment selection. In case of bone-only metastatic disease, ER, PR, and HER2 status assessment may be hampered by Decalcification. We aimed to determine the optimal Decalcification method, and to study discordance of receptor expression between paired primary breast tumors and optimally decalcified bone metastases. First, Decalcification was simulated using acetic acid, hydrochloric/formic acid, and EDTA on 12 primary breast carcinomas. ER, PR, and HER2 immunohistochemistry (IHC) and HER2 in situ hybridization (ISH) were assessed, before and after the 3 Decalcification methods. EDTA was considered the optimal method, as it did not affect IHC and as ISH failed in only 1/16 cases. Hydrochloric/formic acid altered ER and PR results, and, with acetic acid and hydrochloric/formic acid, ISH failed in, respectively, 94% and 100%. Second, ER, PR, and HER2 IHC was performed in paired primary tumors and EDTA-decalcified bone metastases obtained from patients with first presentation of MBC. Clinically relevant discordance was defined as changed receptor status with treatment implications. Paired samples of 77 patients, participating in the IMPACT-MBC trial, were evaluable. Hormonal receptor expression change was clinically relevant in 6 patients (7.9%) and HER2 expression change in 1 patient (1.3%). This study shows that EDTA Decalcification minimally affects receptor expression results. The incidence of clinically relevant discordance between the primary tumor and bone metastases is low. These findings support that bone biopsies can reliably be used to assess receptor status.
